IDH1 and glioma: The encouraging data on talampanel have fostered studies with PER in glioma-associated epilepsy, and since the description of PER administered to a patient with IDH1-wildtype and MGMT-unmethylated glioblastoma who became seizure-free and survived for 18 months [159], a number of rather small studies have explored PER efficacy in glioma-associated seizures (Table 1).